or Try an Advanced Search...

    Technical Analysis for XRTX - XORTX Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 3.05 -3.78% -0.12
    XRTX closed down 3.78 percent on Thursday, April 18, 2024, on 54 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical XRTX trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion -3.78%
    Wide Bands Range Expansion -3.78%
    Oversold Stochastic Weakness -3.78%
    NR7 Range Contraction -1.61%
    Narrow Range Bar Range Contraction -1.61%
    Doji - Bullish? Reversal -1.61%
    Older End-of-Day Signals for XRTX ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Lower Bollinger Band about 16 hours ago
    Down 10% about 16 hours ago
    Down 5% about 17 hours ago
    Down 3% about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    XRTX Chart by TradingView
    Basic chart:

    Profile

    XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
    Classification
    Sector: Technology
    Industry: Data Storage
    Keywords: Pharmaceutical Organ Systems Infection Kidney Disease Kidney Diabetic Nephropathy Autosomal Dominant Polycystic Kidney Disease

    Is XRTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 8 XORTX Announces Participation in Spring 2024 Investor Conferences
    Mar 27 XORTX Announces New Clinical Advisory Board Member
    Mar 19 XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
    Mar 19 XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
    Mar 11 XORTX Reprices Warrants Issued in Connection with Previous Private Placements
    Mar 4 XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
    Feb 15 XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units
    Feb 2 XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
    Jan 15 XORTX Announces $2 Million Public Offering
    Jan 4 Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    See more XRTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 72.09
    52 Week Low 1.98
    Average Volume 57,062
    200-Day Moving Average 22.21
    50-Day Moving Average 3.58
    20-Day Moving Average 3.62
    10-Day Moving Average 3.44
    Average True Range 0.42
    RSI (14) 40.12
    ADX 24.98
    +DI 15.30
    -DI 30.87
    Chandelier Exit (Long, 3 ATRs) 4.11
    Chandelier Exit (Short, 3 ATRs) 4.08
    Upper Bollinger Bands 4.47
    Lower Bollinger Band 2.77
    Percent B (%b) 0.17
    BandWidth 47.01
    MACD Line -0.20
    MACD Signal Line -0.11
    MACD Histogram -0.091
    Fundamentals Value
    Market Cap 6.1 Million
    Num Shares 2 Million
    EPS -3.60
    Price-to-Earnings (P/E) Ratio -0.85
    Price-to-Sales 0.00
    Price-to-Book 0.76
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.55
    Resistance 3 (R3) 3.53 3.34 3.46
    Resistance 2 (R2) 3.34 3.22 3.35 3.44
    Resistance 1 (R1) 3.20 3.14 3.11 3.22 3.41
    Pivot Point 3.01 3.01 2.97 3.02 3.01
    Support 1 (S1) 2.87 2.89 2.78 2.89 2.69
    Support 2 (S2) 2.68 2.81 2.69 2.67
    Support 3 (S3) 2.54 2.68 2.64
    Support 4 (S4) 2.56